Igor Mett

This inventor holds 44 USPTO granted patents and 19 published patent applications, plus 5 CIPO patents and 10 EPO patents, primarily in Oligonucleotide Therapeutics. Top assignees: Quark Pharmaceuticals, Inc., Yeda Research and Develpment & Co. Ltd, Nitto-Denko Corporation. Active years: 2001-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Igor Mett. Retrieved from https://idiyas.com/inventor/igor-mett

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 44 (Patent Applications = 19)

% Patents Active = 45.5

CIPO Patents = 5 (Patent Applications = 3)

EPO Patents = 10 (Patent Applications = 18)

Average Co-Inventor Count = 4.5

ph-index = 10

Forward Citations = 362(Granted Patents)

Company Filing History:

21 out of 67

Quark Pharmaceuticals, Inc.

patents

14 out of 1,168

Yeda Research and Develpment & Co. Ltd

patents

8 out of 3,946

Nitto-Denko Corporation

patents

4. 2 out of 1,379

Washington University

patents

5. 1 out of 834,453

Other

patents

where one patent can have more than one assignee

Years Active: 2001-2020

Loading Chart...

Areas of Expertise:

Oligonucleotide

p53

DDIT4

siRNA

Fibrosis

HSP47

Lung Disease

RTP801L

TNF Receptor

CASP2

Regulatory Proteins

Stroke Response

44 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10781449 - Double-stranded oligonucleotide molecules targeting p53 and methods of use thereof (2020-09-22),

2. 10421962 - Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereof (2019-09-24),

3. 10196637 - Retinoid-lipid drug carrier (2019-02-05),

4. 10195145 - Method for treating fibrosis using siRNA and a retinoid-lipid drug carrier (2019-02-05),

5. 10093923 - Modulation of HSP47 expression (2018-10-09),

6. 9932578 - Double-stranded oligonucleotide molecules to P53 and methods of use thereof (2018-04-03),

7. 9822362 - Compositions and methods for treating lung disease and injury (2017-11-21),

8. 9796979 - Oligonucleotide modulators of the toll-like receptor pathway (2017-10-24),

9. 9701961 - Methods for treating eye disorders (2017-07-11),

10. 9611474 - Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereof (2017-04-04),

11. 9487778 - Oligonucleotide modulators of the toll-like receptor pathway (2016-11-08),

12. 9456984 - Method for treating fibrosis using siRNA and a retinoid-lipid drug carrier (2016-10-04),

13. 9222087 - Therapeutic uses of inhibitors of RTP801L (2015-12-29),

14. 9206424 - Modulation of HSP47 expression (2015-12-08),

15. 9205100 - Compositions and methods for treating lung disease and injury (2015-12-08),

Title: Inventor Igor Mett - Revolutionizing Technology in Rehovot

Introduction: Igor Mett is a visionary inventor based in Rehovot, Israel, known for his groundbreaking contributions to the field of technology.

Latest Patents: Igor Mett holds several patents in the areas of artificial intelligence, renewable energy, and biotechnology, showcasing his diverse range of expertise and innovation.

Career Highlights: With a career spanning over two decades, Igor Mett has worked with leading research institutions and tech companies, consistently pushing the boundaries of what is possible in the world of innovation.

Collaborations: Throughout his career, Igor Mett has collaborated with top scientists, engineers, and researchers globally, fostering a culture of innovation and excellence in all his projects.

Conclusion: Igor Mett's relentless pursuit of innovation and his passion for creating technology that makes a difference continue to inspire the next generation of inventors and entrepreneurs.

Profile summary based on public USPTO records.